Publications by authors named "David Aagaard"
Objective: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.
Methods: We performed a nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, comprising all patients treated with biologics or novel small-molecule therapies for RA, AxSpA, PsA, and psoriasis between January 2015 through May 2021 (DANBIO) and November 2009 to November 2019 (DERMBIO).
Objectives: To examine the association between health-related quality of life (HRQoL) and mortality in patients with heart failure (HF).
Background: The potential association of HRQoL and mortality in patients with HF is unclear. We investigated this association in The Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillators (ICD) in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH).
Importance: New-onset postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. However, data on the long-term risk of thromboembolism in patients who develop POAF after heart valve surgery are conflicting. In addition, data on stroke prophylaxis in this setting are lacking.
View Article and Find Full Text PDFArticle Synopsis
- The Danish Study (DANISH) aimed to evaluate the impact of implantable cardioverter-defibrillators (ICD) on health-related quality of life (HRQoL) in patients with non-ischaemic systolic heart failure, despite finding no overall effect on mortality.
- In the study, 1116 patients were randomly assigned to receive either ICD implantation or standard care, with HRQoL assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) over 8 months.
- Results indicated that there were no significant differences in HRQoL improvements between the ICD group and the control group, suggesting that ICD implantation did not enhance quality of life for these patients.